A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies

S. Y. Kim, J. W. Theunissen, J. Balibalos, S. Liao-Chan, M. C. Babcock, T. Wong, B. Cairns, D. Gonzalez, E. H. Van Der Horst, M. Perez, Z. Levashova, L. Chinn, J. A. D'Alessio, Mark Flory, A. Bermudez, D. Y. Jackson, E. Ha, J. Monteon, M. F. Bruhns, G. ChenT. S. Migone

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Although several new therapeutic approaches have improved outcomes in the treatment of hematologic malignancies, unmet need persists in acute myeloid leukemia (AML), multiple myeloma (MM) and non-Hodgkin's lymphoma. Here we describe the proteomic identification of a novel cancer target, SAIL (Surface Antigen In Leukemia), whose expression is observed in AML, MM, chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). While SAIL is widely expressed in CLL, AML, MM, DLBCL and FL patient samples, expression in cancer cell lines is mostly limited to cells of AML origin. We evaluated the antitumor activity of anti-SAIL monoclonal antibodies, 7-1C and 67-7A, conjugated to monomethyl auristatin F. Following internalization, anti-SAIL antibody-drug conjugates (ADCs) exhibited subnanomolar IC50 values against AML cell lines in vitro. In pharmacology studies employing AML cell line xenografts, anti-SAIL ADCs resulted in significant tumor growth inhibition. The restricted expression profile of this target in normal tissues, the high prevalence in different types of hematologic cancers and the observed preclinical activity support the clinical development of SAIL-targeted ADCs.

Original languageEnglish (US)
Article numbere316
JournalBlood cancer journal
Volume5
Issue number5
DOIs
StatePublished - May 29 2015
Externally publishedYes

Fingerprint

Hematologic Neoplasms
Drug Delivery Systems
Surface Antigens
Acute Myeloid Leukemia
Leukemia
Antibodies
Multiple Myeloma
Follicular Lymphoma
Lymphoma, Large B-Cell, Diffuse
Myeloid Cells
B-Cell Chronic Lymphocytic Leukemia
Cell Line
Neoplasms
Therapeutics
Pharmaceutical Preparations
Heterografts
Proteomics
Non-Hodgkin's Lymphoma
Inhibitory Concentration 50
Monoclonal Antibodies

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Kim, S. Y., Theunissen, J. W., Balibalos, J., Liao-Chan, S., Babcock, M. C., Wong, T., ... Migone, T. S. (2015). A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies. Blood cancer journal, 5(5), [e316]. https://doi.org/10.1038/bcj.2015.39

A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies. / Kim, S. Y.; Theunissen, J. W.; Balibalos, J.; Liao-Chan, S.; Babcock, M. C.; Wong, T.; Cairns, B.; Gonzalez, D.; Van Der Horst, E. H.; Perez, M.; Levashova, Z.; Chinn, L.; D'Alessio, J. A.; Flory, Mark; Bermudez, A.; Jackson, D. Y.; Ha, E.; Monteon, J.; Bruhns, M. F.; Chen, G.; Migone, T. S.

In: Blood cancer journal, Vol. 5, No. 5, e316, 29.05.2015.

Research output: Contribution to journalArticle

Kim, SY, Theunissen, JW, Balibalos, J, Liao-Chan, S, Babcock, MC, Wong, T, Cairns, B, Gonzalez, D, Van Der Horst, EH, Perez, M, Levashova, Z, Chinn, L, D'Alessio, JA, Flory, M, Bermudez, A, Jackson, DY, Ha, E, Monteon, J, Bruhns, MF, Chen, G & Migone, TS 2015, 'A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies', Blood cancer journal, vol. 5, no. 5, e316. https://doi.org/10.1038/bcj.2015.39
Kim SY, Theunissen JW, Balibalos J, Liao-Chan S, Babcock MC, Wong T et al. A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies. Blood cancer journal. 2015 May 29;5(5). e316. https://doi.org/10.1038/bcj.2015.39
Kim, S. Y. ; Theunissen, J. W. ; Balibalos, J. ; Liao-Chan, S. ; Babcock, M. C. ; Wong, T. ; Cairns, B. ; Gonzalez, D. ; Van Der Horst, E. H. ; Perez, M. ; Levashova, Z. ; Chinn, L. ; D'Alessio, J. A. ; Flory, Mark ; Bermudez, A. ; Jackson, D. Y. ; Ha, E. ; Monteon, J. ; Bruhns, M. F. ; Chen, G. ; Migone, T. S. / A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies. In: Blood cancer journal. 2015 ; Vol. 5, No. 5.
@article{5f74325fbd914b1b9a79c841466cbd36,
title = "A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies",
abstract = "Although several new therapeutic approaches have improved outcomes in the treatment of hematologic malignancies, unmet need persists in acute myeloid leukemia (AML), multiple myeloma (MM) and non-Hodgkin's lymphoma. Here we describe the proteomic identification of a novel cancer target, SAIL (Surface Antigen In Leukemia), whose expression is observed in AML, MM, chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). While SAIL is widely expressed in CLL, AML, MM, DLBCL and FL patient samples, expression in cancer cell lines is mostly limited to cells of AML origin. We evaluated the antitumor activity of anti-SAIL monoclonal antibodies, 7-1C and 67-7A, conjugated to monomethyl auristatin F. Following internalization, anti-SAIL antibody-drug conjugates (ADCs) exhibited subnanomolar IC50 values against AML cell lines in vitro. In pharmacology studies employing AML cell line xenografts, anti-SAIL ADCs resulted in significant tumor growth inhibition. The restricted expression profile of this target in normal tissues, the high prevalence in different types of hematologic cancers and the observed preclinical activity support the clinical development of SAIL-targeted ADCs.",
author = "Kim, {S. Y.} and Theunissen, {J. W.} and J. Balibalos and S. Liao-Chan and Babcock, {M. C.} and T. Wong and B. Cairns and D. Gonzalez and {Van Der Horst}, {E. H.} and M. Perez and Z. Levashova and L. Chinn and D'Alessio, {J. A.} and Mark Flory and A. Bermudez and Jackson, {D. Y.} and E. Ha and J. Monteon and Bruhns, {M. F.} and G. Chen and Migone, {T. S.}",
year = "2015",
month = "5",
day = "29",
doi = "10.1038/bcj.2015.39",
language = "English (US)",
volume = "5",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies

AU - Kim, S. Y.

AU - Theunissen, J. W.

AU - Balibalos, J.

AU - Liao-Chan, S.

AU - Babcock, M. C.

AU - Wong, T.

AU - Cairns, B.

AU - Gonzalez, D.

AU - Van Der Horst, E. H.

AU - Perez, M.

AU - Levashova, Z.

AU - Chinn, L.

AU - D'Alessio, J. A.

AU - Flory, Mark

AU - Bermudez, A.

AU - Jackson, D. Y.

AU - Ha, E.

AU - Monteon, J.

AU - Bruhns, M. F.

AU - Chen, G.

AU - Migone, T. S.

PY - 2015/5/29

Y1 - 2015/5/29

N2 - Although several new therapeutic approaches have improved outcomes in the treatment of hematologic malignancies, unmet need persists in acute myeloid leukemia (AML), multiple myeloma (MM) and non-Hodgkin's lymphoma. Here we describe the proteomic identification of a novel cancer target, SAIL (Surface Antigen In Leukemia), whose expression is observed in AML, MM, chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). While SAIL is widely expressed in CLL, AML, MM, DLBCL and FL patient samples, expression in cancer cell lines is mostly limited to cells of AML origin. We evaluated the antitumor activity of anti-SAIL monoclonal antibodies, 7-1C and 67-7A, conjugated to monomethyl auristatin F. Following internalization, anti-SAIL antibody-drug conjugates (ADCs) exhibited subnanomolar IC50 values against AML cell lines in vitro. In pharmacology studies employing AML cell line xenografts, anti-SAIL ADCs resulted in significant tumor growth inhibition. The restricted expression profile of this target in normal tissues, the high prevalence in different types of hematologic cancers and the observed preclinical activity support the clinical development of SAIL-targeted ADCs.

AB - Although several new therapeutic approaches have improved outcomes in the treatment of hematologic malignancies, unmet need persists in acute myeloid leukemia (AML), multiple myeloma (MM) and non-Hodgkin's lymphoma. Here we describe the proteomic identification of a novel cancer target, SAIL (Surface Antigen In Leukemia), whose expression is observed in AML, MM, chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). While SAIL is widely expressed in CLL, AML, MM, DLBCL and FL patient samples, expression in cancer cell lines is mostly limited to cells of AML origin. We evaluated the antitumor activity of anti-SAIL monoclonal antibodies, 7-1C and 67-7A, conjugated to monomethyl auristatin F. Following internalization, anti-SAIL antibody-drug conjugates (ADCs) exhibited subnanomolar IC50 values against AML cell lines in vitro. In pharmacology studies employing AML cell line xenografts, anti-SAIL ADCs resulted in significant tumor growth inhibition. The restricted expression profile of this target in normal tissues, the high prevalence in different types of hematologic cancers and the observed preclinical activity support the clinical development of SAIL-targeted ADCs.

UR - http://www.scopus.com/inward/record.url?scp=84989325782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989325782&partnerID=8YFLogxK

U2 - 10.1038/bcj.2015.39

DO - 10.1038/bcj.2015.39

M3 - Article

C2 - 26024286

AN - SCOPUS:84989325782

VL - 5

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 5

M1 - e316

ER -